Allergan (AGN), Adamas Pharma Enter NAMZARIC Patent Suit Settlement with Amneal
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Allergan plc (NYSE: AGN) announced that its subsidiaries Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd. and Allergan USA, along with Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), have entered into a settlement agreement with Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC.
The settlement relates to a patent infringement litigation brought by Forest and Adamas in response to Amneal's abbreviated new drug application (ANDA) seeking approval to market generic versions of Allergan's NAMZARIC® (memantine and donepezil hydrochlorides) extended-release, a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI). It is Allergan's understanding that Amneal is the first applicant to file an ANDA containing a paragraph IV certification regarding NAMZARIC®.
This settlement provides additional clarity for the patent-protected life of NAMZARIC®. Under the terms of the settlement agreement, and subject to review of the settlement terms by the U.S. Federal Trade Commission, Forest and Adamas will grant Amneal a license to market generic versions of NAMZARIC® beginning on January 1, 2025, following receipt by Amneal of final approval from the U.S. Food and Drug Administration (FDA) on its ANDA for generic NAMZARIC®. Alternatively, under certain circumstances, Amneal has an option to launch an authorized generic version of NAMZARIC® beginning on January 1, 2026. Other terms of the settlement were not disclosed.
Similar patent infringement litigation brought by Allergan, Forest and Adamas against Amerigen Pharmaceuticals, Inc. and Amerigen Pharmaceuticals Ltd., which have filed an ANDA seeking approval to market generic versions of NAMZARIC® remains pending in the U.S. District Court for the District of Delaware.
"Allergan is proud of its commitment to providing therapies and advancing the development of new treatments that can help the millions of patients and their caregivers living with Alzheimer's disease," said Bill Meury, Chief Commercial Officer, Allergan. "Our recently announced expanded label for NAMZARIC® allows patients with moderate-to-severe Alzheimer's disease, who are currently stabilized on Aricept, to start combination therapy directly with NAMZARIC®. Approximately 75 percent of patients diagnosed with Alzheimer's disease are in the moderate-to-severe stage of the disease and yet only about one-third of these patients are currently treated with combination therapy."
Allergan is also focused on developing a number of new compounds for the treatment of Alzheimer's disease, including first-in-class selective small molecule agonists targeting muscarinic M1 and M4 receptors in the brain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan (AGN) Enters DELZICOL Patent Settlement Agreement
- Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
- Celgene (CELG) to Acquire Acetylon Pharmaceuticals
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!